Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Pneumococcal disease
NITAG documentation
2021
Clear all
Type of publications
NITAG documentation
(165)
SAGE documentation
(6)
Systematic reviews (SYSVAC)
(236)
Topics
Agenda & Minutes
(2)
Background paper
(27)
Recommendation
(136)
Regions
Africa
(16)
Americas
(61)
Europe
(75)
South-East Asia
(2)
Western Pacific
(11)
Countries
Argentina
(1)
Australia
(11)
Belgium
(16)
Bolivia
(2)
Burkina Faso
(1)
Canada
(15)
Chile
(9)
China
(1)
Denmark
(1)
France
(16)
Germany
(8)
India
(1)
Ireland
(7)
Netherlands
(6)
Nigeria
(1)
Senegal
(2)
Spain
(1)
Sweden
(2)
Uganda
(12)
United Kingdom
(18)
United States of America
(34)
Diseases
COVID-19
(164)
Pneumococcal disease
(1)
Ebola
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Influenza
(5)
Poliomyelitis
(2)
Rotavirus
(3)
Varicella
(1)
Publication date
2021
(165)
2024
(1)
2023
(28)
2022
(79)
2020
(85)
2019
(7)
2018
(13)
2017
(5)
2016
(3)
2015
(5)
2014
(5)
2013
(3)
2012
(2)
2011
(2)
2010
(7)
2008
(3)
2006
(1)
2005
(1)
2004
(2)
2003
(3)
2002
(2)
1997
(1)
Target population
Adults
(3)
Children
(3)
Older adults
(1)
Pregnant women
(4)
Risk group
(2)
Available to download in languages
English (EN)
(112)
French (FR)
(37)
Spanish (ES)
(12)
German (DE)
(7)
Swedish (SV)
(1)
165 results found
2021
∙
Comité Nacional de Inmunización (CNI)
Vaccination, prevention against COVID in children under 12 years old in Bolivia
2021
∙
Comité Nacional de Inmunización (CNI)
Vaccination of pregnant women
2021
∙
ACIP
Adverse events among children ages 5–11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS)
2021
∙
ATAGI
ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns - 8 April, 2021
2021
∙
ACIP
COVID-19 Vaccine Safety Technical (VaST) Work Group
2021
∙
ACIP
Update on Omicron Variant
2021
∙
ACIP
Updates on Thrombosis with Thrombocytopenia Syndrome (TTS)
2021
∙
ACIP
Updates to the benefit/risk assessment for Janssen COVID-19 vaccines
2021
∙
CAVEI
CAVEI RECOMMENDATION ON COVID-19 VACCINATION IN CHILDREN FROM 6 YEARS OLD - 7 September 2021
2021
Enhancing COVID-19 Vaccine Acceptance in Canada
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register